2024-518355-36-01
Not Yet Recruiting
Phase 1
Phase I/II study to determine the safety, immunogenicity and efficacy of Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination (HEB-PEP-Study) - HEB-PEP
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1 site in 1 country24 target enrollmentNovember 27, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Enrollment
- 24
- Locations
- 1
- Status
- Not Yet Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Sonja buschow
Scientific
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Active, Not Recruiting
Phase 1
A clinical trial to assess the safety, immune response, and protection against infection of novel malaria vaccines.Plasmodium falciparum infectionTherapeutic area: Diseases [C] - Parasitic Diseases [C03]EUCTR2017-001049-28-GBniversity of Oxford, CTRG18
Active, Not Recruiting
N/A
Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine. - LSA3-trialP. falciparum infection (malaria)EUCTR2006-001743-66-NLINSTITUT PASTEUR, Biomedical Parasitology Unit
Completed
N/A
To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult MeNot ApplicableKCT0000540Eubiologics20
Active, Not Recruiting
Phase 1
A phase I study to evaluate safety and immunogenicity of recombinant protein candidate vaccine against SARS-CoV-2 in healthy volunteers.SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2021-001411-82-ESABORATORIOS HIPRA, S.A.30
Completed
Phase 1
A Phase 1/2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults and elderly subjectsPrevention of COVID-19JPRN-jRCT2071200110Inoguchi Akihiro152